本研究的目的是评估临床、影像学和/或生化可疑神经内分泌肿瘤（NET）患者的生长抑素受体PET的产量。本分析包括作为前瞻性、单臂登记研究（NCT03873870）中未经证实的NET初步诊断的患者，该研究评估了68Ga-DOTATATE PET/CT在NETs管理中的实用性。本队列的纳入标准包括生物标志物升高和/或临床表现可疑NET，并且常规横断面成像阴性，或常规成像上存在可疑NET的病灶不适合活检。排除具有NET组织学确诊的患者。从2019年4月至2022年3月，纳入了220名平均年龄（±标准差）59.5±16.1岁的生化、形态和/或临床可疑NET患者。总体而言，132/220患者（60%）的68Ga-DOTATATE PET/CT结果呈阳性。68Ga-DOTATATE PET/CT在171例有放射学可疑异常的患者中，证实了123例（71.9%）的类2型生长抑素受体过度表达肿瘤。胰腺、小肠/肠系膜、肾上腺和其他部位的阳性率分别为96例中的78例（81.2%）、57例中的38例（66.7%）、7例中的7例（100%）和11例中的1例（9.1%）。对于49例临床和/或生化可疑NET患者，68Ga-DOTATATE PET/CT呈阳性的有9例（18.4%）。68Ga-DOTATATE PET/CT在近3/4形态可疑NET患者中呈阳性，在胰腺和小肠或肠系膜肿块患者中产量最高，并且在近1/6临床和/或生化可疑NET患者中呈阳性。 版权所有©2023 Wolters Kluwer Health，Inc. 保留所有权利。

The aim of this study was to assess the yield of somatostatin receptor PET in patients with clinical, imaging, and/or biochemical suspicion of a neuroendocrine tumor (NET).This analysis includes patients referred for the initial diagnosis of an unconfirmed NET, as part of a prospective, single-arm registry study (NCT03873870) assessing the utility of 68Ga-DOTATATE PET/CT in the management of NETs. Inclusion criteria to this cohort consisted of elevated biomarkers and/or clinical presentation suspicious for a NET, with negative conventional cross-sectional imaging, or presence of a lesion suspicious for a NET on conventional imaging, not amenable for biopsy. Patients with histological confirmation of a NET were excluded.There were 220 patients included between April 2019 and March 2022 with a mean age ± SD of 59.5 ± 16.1 years with biochemical, morphological, and/or clinical suspicion of a NET. Overall, 132/220 patients (60%) had a positive 68Ga-DOTATATE PET/CT. 68Ga-DOTATATE PET/CT confirmed a type 2 somatostatin receptor overexpressing tumor in 123/171 (71.9%) of patients with a radiographically suspicious abnormality. The positivity rate for pancreatic, small bowel/mesenteric, adrenal, and other sites was 78/96 (81.2%), 38/57 (66.7%), 7/7 (100%), and 1/11 (9.1%), respectively. 68Ga-DOTATATE PET/CT was positive in 9/49 (18.4%) of those with a biochemical and/or clinical suspicion of a NET.68Ga-DOTATATE PET/CT is positive in nearly 3 of 4 patients with morphological suspicion of a NET, with the highest yield in those with pancreatic and small bowel or mesenteric masses, and in approximately 1 of 6 patients with biochemical and/or clinical suspicion of a NET.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.